Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | AHR | P35869 | 4/20 | 0.46 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25651943 | 0.86 | GAA (0.67) | GAAAHRCD44ALDH1A1MAPT | |
| SCHEMBL9629823 | 0.80 | GAA (0.67) | GAAAHRCD44ALDH1A1MAPT | |
| SCHEMBL1098600 | 0.79 | HSD17B10 (0.46) | GAAAHRALDH1A1MAPTMEN1 | |
| SCHEMBL14272795 | 0.79 | CD44 (0.65) | GAAAHRCD44ALDH1A1MAPT | |
| SCHEMBL1100846 | 0.79 | AHR (0.39) | GAAAHRCD44ALDH1A1MAPT | |
| SCHEMBL3339256 | 0.79 | KDM1A (0.40) | GAAAHRALDH1A1MAPTMEN1 | |
| SCHEMBL3168767 | 0.79 | GAA (0.43) | GAAAHRCD44ALDH1A1MAPT | |
| SCHEMBL5238545 | 0.79 | CD44 (0.65) | GAAAHRCD44ALDH1A1MAPT | |
| SCHEMBL11281295 | 0.77 | AHR (0.58) | GAAAHRALDH1A1CA1CA2 | |
| SCHEMBL203217 | 0.77 | GAA (0.71) | GAAAHRCD44ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5021573-A | Heterocyclic pigments and dyes | SANDOZ LTD. (CH) | 1991-06-04 | — | — | US | claimed |
| EP-4629980-A1 | ANTIMICROBIAL COMPOUNDS | SRI International (US) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024123663-A1 | ANTIMICROBIAL COMPOUNDS | SRI INTERNATIONAL (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123663-A1 | ANTIMICROBIAL COMPOUNDS | SRI INTERNATIONAL (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20230061841-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11091451-B2 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018106636-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106636-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2393781-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010072599-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-3975534-A | Pharmaceutical compositions useful for treating tick infestation in animals which contain 2-aryliminopyrrolidines or their salts as the active agent | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | SHMT1, SHMT2, BHMT | GAA 1802/4885AHR 1629/4885CD44 460/4885 |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | GAA 4302/4885AHR 1187/4885CD44 3645/4885 |
| US-20230061841-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | GAA 1802/4885AHR 1629/4885CD44 460/4885 |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | GAA 1802/4885AHR 1629/4885CD44 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.